oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Preserved beta-Cell Function in Type 1 Diabetes by Mesenchymal Stromal Cells
Uppsala Univ, Dept Med Cell Biol, Uppsala, Sweden.;Uppsala Univ, Dept Med Sci, Uppsala, Sweden..
Orebro University Hospital. Internal Med, Orebro.
Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden..
Karolinska Inst, Dept Lab Med, Stockholm, Sweden..
2015 (English)In: Diabetes, ISSN 0012-1797, E-ISSN 1939-327X, Vol. 64, no 2, 587-592 p.Article in journal (Refereed) Published
Abstract [en]

The retention of endogenous insulin secretion in type 1 diabetes is an attractive clinical goal, which opens possibilities for long-term restoration of glucose metabolism. Mesenchymal stromal cells (MSCs) constitute, based on animal studies, a promising interventional strategy for the disease. This prospective clinical study describes the translation of this cellular intervention strategy to patients with recent-onset type 1 diabetes. Twenty adult patients with newly diagnosed type 1 diabetes were enrolled and randomized to MSC treatment or to the control group. Residual beta-cell function was analyzed as C-peptide concentrations in blood in response to a mixed-meal tolerance test (MMTT) at 1-year follow-up. In contrast to the patients in the control arm, who showed loss in both C-peptide peak values and C-peptide when calculated as area under the curve during the 1st year, these responses were preserved or even increased in the MSC-treated patients. Importantly, no side effects of MSC treatment were observed. We conclude that autologous MSC treatment in new-onset type 1 diabetes constitutes a safe and promising strategy to intervene in disease progression and preserve beta-cell function.

Place, publisher, year, edition, pages
American Diabetes Association , 2015. Vol. 64, no 2, 587-592 p.
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:oru:diva-56336DOI: 10.2337/db14-0656ISI: 000348827100026PubMedID: 25204974OAI: oai:DiVA.org:oru-56336DiVA: diva2:1081675
Available from: 2017-03-14 Created: 2017-03-14 Last updated: 2017-03-14Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Schwarcz, Erik
By organisation
Orebro University Hospital
In the same journal
Diabetes
Endocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 4 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf